Aardvark Therapeutics, Inc.
AARDAardvark Therapeutics, Inc. in brief
Aardvark Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $32 M on 30 October 2026, which makes it the 22,888th largest listed company in the world and the 4,028th largest in the USA on this site. It employs about 40 people and Tien-Li Lee is its chief executive. Its shares trade under the symbol AARD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Aardvark Therapeutics, Inc.
We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the chemicals in food and participate in the gut-brain axis. Our research has shown that activating these receptors can induce the secretion of endogenous signaling molecules, including cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1).
From the company's annual report filed with the US SEC: read the report
Aardvark Therapeutics, Inc. timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 13 February 2025; shares registered for exchange trading on 10 February 2025.
Events of Aardvark Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,261 (Aug 2026) · #3,455 (Oct 2026) · #4,031 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.3×
- Free cash flow yield
- -172.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -54.0%
- Liabilities / assets
- 9.0%
- Profit per employee
- $-1.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-63M | $-58M | — |
| Dec 2024 | — | — | $-23M | $-21M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-54M | $0M | $-54M | $-2.93 | — |
| Dec 2024 | $-18M | $0M | $-18M | $-5.15 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-19M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 23, 20268-KCurrent reportOther events
- Oct 22, 20268-KCurrent reportOther events
- Oct 8, 20268-KCurrent reportDirectors or officers changed · Other events
- Aug 17, 20268-KCurrent reportShareholder vote
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 10, 2026DEF 14AProxy statement
- Jun 12, 20268-KCurrent reportDirectors or officers changed
- May 14, 20268-KCurrent reportOther events
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Mar 24, 20268-KCurrent reportMaterial agreement
Official filings of Aardvark Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-63 M
- Net income
- $-58 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $117 M
- Total liabilities
- $11 M
- Total equity
- $107 M
As of December-2025
Top 76 institutional investors in Aardvark Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Decheng Capital LLC | 3,917,299 | 0 (0.00%) | 17.90% | $21 M | Nov 13, 2026 |
| 2 | Laurion Capital Management LP | 1,034,459 | 0 (0.00%) | 4.73% | $5 M | Oct 30, 2026 |
| 3 | Citadel Advisors LLC | 975,028 | -308,138 (-24.01%) | 4.46% | $5 M | Nov 16, 2026 |
| 4 | EcoR1 Capital, LLC | 720,028 | +323,834 (+81.74%) | 3.29% | $4 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 557,926 | -4,951 (-0.88%) | 2.55% | $3 M | Nov 13, 2026 |
| 6 | ExodusPoint Capital Management, LP | 316,427 | New | 1.45% | $2 M | Nov 16, 2026 |
| 7 | BlackRock, Inc. | 194,620 | +7,575 (+4.05%) | 0.89% | $1 M | Nov 13, 2026 |
| 8 | Geode Capital Management, LLC | 139,007 | -10,837 (-7.23%) | 0.64% | $1 M | Nov 6, 2026 |
| 9 | Marshall Wace, LLP | 132,204 | +113,128 (+593.04%) | 0.60% | $1 M | Nov 13, 2026 |
| 10 | Jacobs Levy Equity Management, Inc | 130,165 | New | 0.59% | $1 M | Nov 16, 2026 |
| 11 | Two Sigma Investments, LP | 129,577 | +21,200 (+19.56%) | 0.59% | $1 M | Nov 16, 2026 |
| 12 | AQR Capital Management LLC | 114,053 | -366,196 (-76.25%) | 0.52% | $1 M | Nov 16, 2026 |
| 13 | Raymond James Financial Inc | 92,892 | +13,608 (+17.16%) | 0.42% | $0 M | Nov 12, 2026 |
| 14 | Cantor Fitzgerald, L. P. | 91,682 | -141,482 (-60.68%) | 0.42% | $0 M | Nov 16, 2026 |
| 15 | Velan Capital Investment Management LP | 85,868 | New | 0.39% | $0 M | Nov 16, 2026 |
| 16 | Vanguard Fiduciary Trust Co | 75,172 | 0 (0.00%) | 0.34% | $0 M | Nov 13, 2026 |
| 17 | Jane Street Group, LLC | 68,636 | +46,172 (+205.54%) | 0.31% | $0 M | Nov 12, 2026 |
| 18 | Millennium Management LLC | 62,454 | -7,494 (-10.71%) | 0.29% | $0 M | Nov 16, 2026 |
| 19 | Susquehanna International Group, LLP | 60,976 | +36,951 (+153.80%) | 0.28% | $0 M | Nov 16, 2026 |
| 20 | State Street Corp | 57,573 | -1,700 (-2.87%) | 0.26% | $0 M | Nov 12, 2026 |
| 21 | J. Goldman & Co LP | 54,127 | +13,627 (+33.65%) | 0.25% | $0 M | Nov 16, 2026 |
| 22 | Adage Capital Partners GP, L.L.C. | 50,000 | -250,000 (-83.33%) | 0.23% | $0 M | Nov 16, 2026 |
| 23 | D. E. Shaw & Co., Inc. | 40,558 | New | 0.19% | $0 M | Nov 16, 2026 |
| 24 | Simplex Trading, LLC | 37,538 | +21,621 (+135.84%) | 0.17% | $0 M | Nov 4, 2026 |
| 25 | Point72 Asset Management, L.P. | 35,456 | +12,584 (+55.02%) | 0.16% | $0 M | Nov 16, 2026 |
Show all 76: investors 26 to 76
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | XTX Topco Ltd | 35,246 | +15,358 (+77.22%) | 0.16% | $0 M | Nov 16, 2026 |
| 27 | Northern Trust Corp | 28,080 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 28 | Barclays PLC | 25,792 | +23,533 (+1041.74%) | 0.12% | $0 M | Nov 6, 2026 |
| 29 | Cresset Asset Management, LLC | 24,000 | -33 (-0.14%) | 0.11% | $0 M | Nov 16, 2026 |
| 30 | Smith, Moore & Co. | 23,725 | +3,725 (+18.62%) | 0.11% | $0 M | Nov 12, 2026 |
| 31 | Bridgeway Capital Management, LLC | 23,602 | -398 (-1.66%) | 0.11% | $0 M | Nov 16, 2026 |
| 32 | Empowered Funds, LLC | 23,602 | New | 0.11% | $0 M | Nov 13, 2026 |
| 33 | FMR LLC | 18,900 | -4 (-0.02%) | 0.09% | $0 M | Nov 10, 2026 |
| 34 | Dimensional Fund Advisors LP | 17,710 | New | 0.08% | $0 M | Nov 4, 2026 |
| 35 | Schonfeld Strategic Advisors LLC | 15,942 | New | 0.07% | $0 M | Nov 16, 2026 |
| 36 | Verdad Advisers, LP | 14,953 | New | 0.07% | $0 M | Nov 16, 2026 |
| 37 | Quadrature Capital Ltd | 12,271 | New | 0.06% | $0 M | Nov 13, 2026 |
| 38 | Gsa Capital Partners LLP | 11,808 | New | 0.05% | $0 M | Nov 16, 2026 |
| 39 | Goldman Sachs Group Inc | 10,465 | -1,776 (-14.51%) | 0.05% | $0 M | Nov 16, 2026 |
| 40 | Trexquant Investment LP | 10,329 | New | 0.05% | $0 M | Nov 16, 2026 |
| 41 | Ieq Capital, LLC | 10,294 | -28,088 (-73.18%) | 0.05% | $0 M | Nov 10, 2026 |
| 42 | Abel Hall, LLC | 10,066 | 0 (0.00%) | 0.05% | $0 M | Oct 19, 2026 |
| 43 | BNP Paribas Financial Markets | 9,971 | +8,663 (+662.31%) | 0.05% | $0 M | Nov 12, 2026 |
| 44 | Morgan Stanley | 7,429 | -22,748 (-75.38%) | 0.03% | $0 M | Nov 13, 2026 |
| 45 | Steward Partners Investment Advisory, LLC | 6,930 | +2,780 (+66.99%) | 0.03% | $0 M | Nov 13, 2026 |
| 46 | Vanguard Global Advisers, LLC | 5,893 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 47 | Arax Advisory Partners | 4,210 | -4,164 (-49.73%) | 0.02% | $0 M | Nov 12, 2026 |
| 48 | China Universal Asset Management Co., Ltd. | 3,993 | +521 (+15.01%) | 0.02% | $0 M | Oct 28, 2026 |
| 49 | Tower Research Capital LLC (TRC) | 2,991 | +490 (+19.59%) | 0.01% | $0 M | Nov 16, 2026 |
| 50 | Jpmorgan Chase & Co | 1,630 | -154 (-8.63%) | 0.01% | $0 M | Nov 12, 2026 |
| 51 | UBS Group AG | 1,436 | -34,203 (-95.97%) | 0.01% | $0 M | Nov 10, 2026 |
| 52 | Russell Investments Group, Ltd. | 1,239 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 53 | Mirae Asset Global Investments Co., Ltd. | 1,118 | +142 (+14.55%) | 0.01% | $0 M | Oct 29, 2026 |
| 54 | Group One Trading LLC | 1,074 | New | 0.00% | $0 M | Nov 10, 2026 |
| 55 | Stone House Investment Management, LLC | 1,000 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 56 | Federated Hermes, Inc. | 646 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 57 | Citigroup Inc | 581 | -25,718 (-97.79%) | 0.00% | $0 M | Nov 4, 2026 |
| 58 | GF Fund Management Co. LTD. | 492 | +40 (+8.85%) | 0.00% | $0 M | Oct 26, 2026 |
| 59 | Hilton Head Capital Partners, LLC | 434 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 60 | GAMMA Investing LLC | 388 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 61 | Royal Bank Of Canada | 376 | +207 (+122.49%) | 0.00% | $0 M | Nov 16, 2026 |
| 62 | PNC Financial Services Group, Inc. | 344 | -5 (-1.43%) | 0.00% | $0 M | Nov 6, 2026 |
| 63 | EverSource Wealth Advisors, LLC | 286 | -488 (-63.05%) | 0.00% | $0 M | Nov 4, 2026 |
| 64 | Allworth Financial LP | 181 | -632 (-77.74%) | 0.00% | $0 M | Nov 17, 2026 |
| 65 | Essential Partners LLC | 160 | -349 (-68.57%) | 0.00% | $0 M | Oct 14, 2026 |
| 66 | Nuveen, LLC | 147 | New | 0.00% | $0 M | Nov 10, 2026 |
| 67 | Rialto Wealth Management, LLC | 84 | New | 0.00% | $0 M | Nov 16, 2026 |
| 68 | Nisa Investment Advisors, LLC | 70 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 69 | Harbour Investments, Inc. | 61 | +8 (+15.09%) | 0.00% | $0 M | Nov 9, 2026 |
| 70 | Rothschild Investment LLC | 48 | -217 (-81.89%) | 0.00% | $0 M | Nov 10, 2026 |
| 71 | True Wealth Design, LLC | 27 | -135 (-83.33%) | 0.00% | $0 M | Oct 13, 2026 |
| 72 | IFP Advisors, Inc | 20 | -427 (-95.53%) | 0.00% | $0 M | Oct 16, 2026 |
| 73 | Farther Finance Advisors, LLC | 17 | -136 (-88.89%) | 0.00% | $0 M | Oct 8, 2026 |
| 74 | Transamerica Financial Advisors, LLC | 14 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 75 | Fortitude Family Office, LLC | 11 | -45 (-80.36%) | 0.00% | $0 M | Oct 14, 2026 |
| 76 | JPL Wealth Management, LLC | 1 | -6 (-85.71%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Aardvark Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 408,670 | $2 M | 1.9% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 140,389 | $1 M | 0.64% | <0.01% | +6.7% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 89,124 | $1 M | 0.41% | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 66,747 | $0 M | 0.30% | <0.01% | +1.5% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 64,981 | $0 M | 0.30% | <0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 42,615 | $0 M | 0.19% | 0.02% | +37% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 24,000 | $0 M | 0.11% | 0.09% | −11% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 22,633 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 22,439 | $0 M | 0.10% | 0.06% | +16% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 18,735 | $0 M | 0.09% | <0.01% | +5.2% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 15,483 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 8,867 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 7,980 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 4,951 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 6,719 | $0 M | 0.03% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 4,636 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 4,479 | $0 M | 0.02% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 4,264 | $0 M | 0.02% | <0.01% | +4.9% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,679 | $0 M | 0.01% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 2,474 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 1,503 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,274 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,472 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 800 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 600 | $0 M | <0.01% | <0.01% | +9.1% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 475 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 469 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 200 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 72 | $0 M | <0.01% | <0.01% | +5.9% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Aardvark Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Nelson SunSee Remarks | Sell10b5-1 plan | -62,000 | $5.180 | $321 K | 35,475 | Form 4 |
| filed | Nelson SunSee Remarks | Sell10b5-1 plan | -14,754 | $5.000 | $74 K | 97,475 | Form 4 |
| filed | Tien-Li LeeChief Executive Officer, Director, 10% owner | Buy | +7,000 | $14.49 | $101 K | 1.55 M | Form 4 |
| filed | Nelson SunChief Financial Officer | Buy | +3,000 | $14.40 | $43 K | 108,484 | Form 4 |
| filed | Bryan JonesChief Operating Officer | Option exercise | +1,250 | $4.240 | $5 K | 1,250 | Form 4 |
| filed | Tien-Li LeeChief Executive Officer, Director, 10% owner | Option exercise | +1,229 | $4.240 | $5 K | 1.54 M | Form 4 |
| filed | Tien-Li LeeChief Executive Officer, Director, 10% owner | Buy | +6,500 | $9.510 | $62 K | 1.54 M | Form 4 |
| filed | Tien-Li LeeChief Executive Officer, Director, 10% owner | Buy | +3,500 | $9.940 | $35 K | 1.54 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Aardvark Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $16.00, raising $94.2M · IPO calendar
Stock splits: 1-for-8.47 reverse split in the period to
Trading halts
- 2026-10-23 13:51 UTC, code LUDP, resumed 13:56 UTC
- 2026-10-23 13:45 UTC, code LUDP, resumed 13:50 UTC
- 2026-10-23 13:39 UTC, code LUDP, resumed 13:44 UTC
- 2026-10-22 20:01 UTC, code T3, resumed 20:35 UTC
- 2026-05-15 13:36 UTC, code LUDP, resumed 13:41 UTC
Fails to deliver
- : 176,079 shares at $1.44
- : 302,948 shares at $1.51
- : 507,252 shares at $1.30
- : 501,028 shares at $1.08
- : 306,616 shares at $1.39
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Aardvark Therapeutics, Inc. scorecard#
Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.3×Price to book 0.3× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-172.2%Free cash flow is -172.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.93 vs -5.15Diluted EPS -2.93 in fiscal 2025 against -5.15 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$58 MNet income -$58 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-221.5%-221.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities10.6×Current ratio 10.61 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year391.1%Diluted shares up 391.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Aardvark Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Revenue | 0—— | — | |
| Research and development | 49+182%— | 17—— | |
| General and administrative | 14+160%— | 5.3—— | |
| Operating expenses | 63+175%— | 23—— | |
| Operating income | −63—— | −23—— | |
| Interest and finance income | 5.1+113%— | 2.4—— | |
| Other non-operating income (expense) | 5.1+134%— | 2.2—— | |
| Income tax | 0—— | 0—— | |
| Net income attributable to shareholders | −58—— | −21—— | |
| Earnings per share, basic | -2.93—— | -5.15—— | |
| Earnings per share, diluted | -2.93—— | -5.15—— | |
| Shares, weighted average (basic) | 20+391%— | 4.0—— | |
| Shares, weighted average (diluted) | 20+391%— | 4.0—— | |
| Balance sheet | |||
| Cash and cash equivalents | 47−23.7%40.2% | 62—79.5% | |
| Short-term investments | 63+424%53.7% | 12—15.5% | |
| Other current assets | 1.9+292%1.6% | 0.5—0.6% | |
| Current assets | 112+50.9%95.5% | 74—95.7% | |
| Right-of-use (leased) assets | 0.4−51.7%0.3% | 0.7—0.9% | |
| Total assets | 117+51.2%100% | 78—100% | |
| Accounts payable | 2.1−9.8%1.8% | 2.3—3.0% | |
| Current liabilities | 11+114%9.0% | 4.9—6.4% | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.4—0.6% | |
| Total liabilities | 11+95.6%9.0% | 5.4—7.0% | |
| Retained earnings | −116—−98.9% | −58—−75.3% | |
| Shareholders' equity | 107—91.0% | −55—−70.5% | |
| Total liabilities and equity | 117+51.2%100% | 78—100% | |
| Shares outstanding | 22+436%— | 4.1—— | |
| Cash-flow statement | |||
| Depreciation and amortization | 0.0+125%— | 0.0—— | |
| Share-based compensation | 3.9+799%— | 0.4—— | |
| Cash from operating activities | −54—— | −18—— | |
| Capital expenditure | −0.1—— | −0.1—— | |
| Cash from investing activities | −50—— | −12—— | |
| Shares issued | 0.2—— | 0—— | |
| Cash from financing activities | 89+8.9%— | 82—— | |
| Report | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | |
| Research and development | 57—— | 16+14.1%— | 10−20.5%— | 17+114%— | 14*—— | 14—— | 13—— | 7.8—— | |
| General and administrative | 19—— | 4.0+2.0%— | 4.6+71.3%— | 5.9+117%— | 4.4*—— | 4.0—— | 2.7—— | 2.7—— | |
| Operating expenses | 76—— | 20+11.4%— | 15−4.8%— | 22+115%— | 19*—— | 18—— | 16—— | 10—— | |
| Operating income | −76—— | −20—— | −15—— | −22—— | −19*—— | −18—— | −16—— | −10—— | |
| Interest and finance income | 3.2—— | 0.5−60.1%— | 0.7−53.3%— | 0.9−24.3%— | 1.1*—— | 1.4—— | 1.5—— | 1.2—— | |
| Other non-operating income (expense) | 3.2—— | 0.5−61.7%— | 0.7−52.9%— | 0.9−24.5%— | 1.1*—— | 1.4—— | 1.5—— | 1.2—— | |
| Net income attributable to shareholders | −73—— | −19—— | −14—— | −22—— | −18*—— | −16—— | −14—— | −9.3—— | |
| Earnings per share, basic | — | -0.88—— | -0.66—— | -0.99—— | — | -0.75—— | -0.66—— | -0.71—— | |
| Earnings per share, diluted | — | -0.88—— | -0.66—— | -0.99—— | — | -0.75—— | -0.66—— | -0.71—— | |
| Shares, weighted average (basic) | 22—— | 22+0.8%— | 22+0.7%— | 22+65.3%— | — | 22—— | 22—— | 13—— | |
| Shares, weighted average (diluted) | 22—— | 22+0.8%— | 22+0.7%— | 22+65.3%— | — | 22—— | 22—— | 13—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 60—93.1% | 60+53.6%93.1% | 74+184%90.7% | 62+136%63.3% | 47—40.2% | 39—29.5% | 26—17.6% | 27—16.9% | |
| Short-term investments | 0.0—0.0% | 0.0−100.0%0.0% | 0.0−100.0%0.0% | 29−76.9%29.2% | 63—53.7% | 87—65.3% | 116—78.5% | 125—79.4% | |
| Other current assets | 3.8—5.8% | 3.8+31.5%5.8% | 6.8+130%8.3% | 2.4−27.7%2.4% | 1.9—1.6% | 2.9—2.1% | 2.9—2.0% | 3.3—2.1% | |
| Current assets | 64—98.9% | 64−50.4%98.9% | 81−44.3%99.0% | 94−39.5%94.9% | 112—95.5% | 129—97.0% | 145—98.2% | 155—98.4% | |
| Right-of-use (leased) assets | 0.5—0.8% | 0.5+21.2%0.8% | 0.6+19.9%0.8% | 0.3−57.2%0.3% | 0.4—0.3% | 0.4—0.3% | 0.5—0.4% | 0.6—0.4% | |
| Total assets | 65—100% | 65−51.4%100% | 81−44.8%100% | 99−37.2%100% | 117—100% | 133—100% | 147—100% | 157—100% | |
| Accounts payable | 1.6—2.5% | 1.6−64.2%2.5% | 2.1−58.7%2.6% | 4.5+75.8%4.6% | 2.1—1.8% | 4.4—3.3% | 5.1—3.4% | 2.6—1.6% | |
| Current liabilities | 7.0—10.9% | 7.0−34.5%10.9% | 6.4−38.1%7.8% | 12+94.2%11.8% | 11—9.0% | 11—8.1% | 10—7.0% | 6.0—3.8% | |
| Lease liabilities (non-current) | 0.2—0.2% | 0.2+37.1%0.2% | 0.3+21.1%0.3% | — | 0—0.0% | 0.1—0.1% | 0.2—0.2% | 0.3—0.2% | |
| Total liabilities | 7.2—11.1% | 7.2−33.7%11.1% | 6.7−36.8%8.2% | 12+83.1%11.8% | 11—9.0% | 11—8.1% | 11—7.2% | 6.3—4.0% | |
| Retained earnings | −171—−264% | −171—−264% | −152—−186% | −138—−139% | −116—−98.9% | −98—−73.8% | −82—−55.6% | −68—−43.1% | |
| Shareholders' equity | 58—88.9% | 58−52.9%88.9% | 75−45.4%91.8% | 87−42.3%88.2% | 107—91.0% | 122—91.9% | 137—92.8% | 151—96.0% | |
| Total liabilities and equity | 65—100% | 65−51.4%100% | 81−44.8%100% | 99−37.2%100% | 117—100% | 133—100% | 147—100% | 157—100% | |
| Shares outstanding | 22—— | 22+0.7%— | 22+0.9%— | 22+0.6%— | 22—— | 22—— | 22—— | 22—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.0—— | 0.0*0.0%— | 0.0*0.0%— | 0.0+120%— | 0.0*—— | 0.0*—— | 0.0*—— | 0.0—— | |
| Share-based compensation | 7.5—— | 2.0+31.6%— | 2.0+208%— | 2.0+760%— | 1.6*—— | 1.5—— | 0.6—— | 0.2—— | |
| Cash from operating activities | −67—— | −14*—— | −18*—— | −19—— | −17*—— | −16*—— | −9.8*—— | −11—— | |
| Capital expenditure | — | 0*—— | — | — | 0*—— | −0.0*—— | −0.1*—— | 0—— | |
| Cash from investing activities | 87—— | 0*−100%— | 29*+206%— | 34—— | 24*—— | 29*—— | 9.4*—— | −113—— | |
| Shares issued | — | 0*—— | — | — | 0.2*—— | 0*—— | — | — | |
| Cash from financing activities | 0.6—— | 0.0*−87.1%— | 0.3*—— | 0.0−100.0%— | 0.3*—— | 0.2*—— | −0.1*—— | 89—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Aardvark Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 8, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Aardvark Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Sr. Project ManagerProject Management Specialists | 1 | $120 K |
Where: San Diego, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aardvark Therapeutics Inc.
How Aardvark Therapeutics, Inc. compares in Biotechnology
- Market cap$32 M · higher than 22% of 726
- Price / book0.3× · lower than 97% of 534
- FCF yield-172.2% · higher than 2% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Aardvark Therapeutics, Inc.🇺🇸 | $32 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 28, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Aardvark Therapeutics, Inc.? Verify and update this profile — free
Show Aardvark Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.